Updated Jul 16, 2026 · Last SEC filing 2026-06-12
JOHNSON & JOHNSON (JNJ) has filed 16 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-12. 2 Form 8-K material event filings were reported by JNJ in the last 90 days. 1 Form 144 notices of proposed sale were filed for JNJ stock. InsiderAlpha tracks every JNJ SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0000200406 |
|---|
| Form 4 filings (90d) | 16 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-06-12 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | S — Open-market sale | 10.0K | $241.15 | $2.41M | SEC | |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | M — Option exercise | 10.0K | $115.67 | $1.16M | SEC | |
| REED JOHN C | EVP, Innovative Medicine, R&D | F — Tax withholding / forfeiture | 11.0K | $229.85 | $2.53M | SEC | |
| REED JOHN C | EVP, Innovative Medicine, R&D | M — Option exercise | 25.3K | $0.00 | — | SEC | |
| Decker Robert J | VP Corporate Controller | M — Option exercise | 4.1K | $115.67 | $471K | SEC | |
| Decker Robert J | VP Corporate Controller | S — Open-market sale | 4.1K | $247.87 | $1.01M | SEC | |
| Schmid Timothy | EVP, WW Chair, MedTech | S — Open-market sale | 1.3K | $245.66 | $325K | SEC | |
| Schmid Timothy | EVP, WW Chair, MedTech | S — Open-market sale | 9.0K | $244.53 | $2.20M | SEC | |
| Schmid Timothy | EVP, WW Chair, MedTech | S — Open-market sale | 13.6K | $244.20 | $3.33M | SEC | |
| Schmid Timothy | EVP, WW Chair, MedTech | M — Option exercise | 13.6K | $115.67 | $1.58M | SEC | |
| Schmid Timothy | EVP, WW Chair, MedTech | M — Option exercise | 9.0K | $129.51 | $1.17M | SEC | |
| REED JOHN C | EVP, Innovative Medicine, R&D | S — Open-market sale | 21.7K | $243.00 | $5.28M | SEC | |
| REED JOHN C | EVP, Innovative Medicine, R&D | S — Open-market sale | 29.9K | $243.00 | $7.27M | SEC | |
| REED JOHN C | EVP, Innovative Medicine, R&D | M — Option exercise | 29.9K | $156.15 | $4.67M | SEC | |
| Wolk Joseph J | Exec VP, CFO | S — Open-market sale | 25.0K | $242.68 | $6.06M | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for JOHNSON & JOHNSON (JNJ). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Wengel Kathryn E | 3 | $3.57M |
| REED JOHN C | 3 | $2.53M |
| Woods Eugene A. | 2 | $37K |
| HEWSON MARILLYN A | 2 | $50K |
| Pinto Daniel E | 2 | $31K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in JNJ insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live JNJ dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.